| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $0 | — | — |
| SG&A Expense | $16K | — | -31.0% |
| Operating Income | -$16K | — | +31.0% |
| Interest Expense | $3K | — | +0.0% |
| Net Income | -$17K | — | +35.4% |
| EPS (Basic) | $0.00 | — | — |
| EPS (Diluted) | $0.00 | — | — |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $165K | +397.0% | — |
| Current Assets | $257K | -4.1% | — |
| Total Assets | $257K | -4.1% | +237.0% |
| Current Liabilities | $481K | +1.3% | -28.7% |
| Total Liabilities | $481K | +1.3% | -28.7% |
| Stockholders' Equity | -$224K | -8.2% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$33K | — | -37.7% |
| Investing Cash Flow | -$130K | — | — |
| +62.6% |